Abbmira Therapeutics AG
Fine-tuning native immunity to treat cancer.
Abbmira Therapeutics activates the immune system of cancer patients to fight tumors. Our small molecule compounds are designed to target and activate a specific target in native immune cells that are critical to fight cancer. Our proof-of-concept experiments confirm our experimental compounds stops cancer growth in mice and we now optimising our therapeutic approach to bring molecules to the clinic in the next 3 years. Abbmira addresses an huge unmet medical need in a growing market, estimated to reach $169B by 2032. Abbmira's founding teamoffers 50+ years of combined experience in business, pharma, and life sciences.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
21.07.2025
Seven startups selected for the Swiss-Israel Lean Launchpad (startupticker.ch)
30.01.2025
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Abbmira Therapeutics AG
Fine-tuning native immunity to treat cancer.
Website:
www.abbmira.com
Headquarter:
Basel
Foundation Date:
September 2024
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
- Drug discovery
- Inflammation
- Research and development
- Small molecule drugs
Support received
